Moss,10 March 2025
Gentian Diagnostics is pleased to announce the launch of the GCAL® Calprotectin Immunoassay with Beckman Coulter Diagnostics to its clinical chemistry platforms. This collaboration illustrates our commitment to enhance diagnostic efficiency for improved treatment decisions.
The Gentian GCAL® Calprotectin Immunoassay enables precise measurement of calprotectin in human plasma and serum. Circulating calprotectin is widely recognized as a sensitive biomarker for detection and assessment of inflammation across a broad range of diseases. This makes it a valuable tool in numerous inflammatory and rheumatic diseases as well as in detection and risk assessment of the inflammatory response in infections, highlighting its broad utility in clinical practice.
"We are pleased to officially announce that Beckman Coulter Diagnostics, a leader in the field of clinical diagnostics, is launching our GCAL® assay," says Matti Heinonen, CEO of Gentian Diagnostics. "This partnership builds on our long-standing relationship with Beckman Coulter and marks a significant milestone in our commitment to advancing market development for circulating calprotectin. By combining our innovative GCAL® assay with Beckman Coulter's industry expertise and reach, we are poised to empower healthcare professionals with more accurate and timely diagnostic tools, enhancing patient care and outcomes."
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within homogenous immunoassays, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analyzers, the company contributes to saving costs and protecting life. Gentian is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.
See also press release on Newsweb.
IR Contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)